Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
Caitriona CahirJeffrey P LealLilja SolnesChiung-Yu HuangAshley CarpenterKaty GaffneyVandana G AbramsonLisa Anne CareyMinetta C LiuMothaffar F RimawiJennifer M SpechtAnna Maria V StornioloVicente ValeroChristos VaklavasIan E KropEric P WinerMelissa CampRobert S MillerAntonio C WolffAshley Cimino-MathewsBen Ho ParkRichard L WahlVered StearnsPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Although the primary objective was not met, early changes in SULmax predict response to PT in estrogen receptor-negative and HER2-positive breast cancer. Once optimized, this quantitative imaging strategy may facilitate tailoring of therapy in this setting.
Keyphrases
- estrogen receptor
- positive breast cancer
- epidermal growth factor receptor
- high resolution
- tyrosine kinase
- metastatic breast cancer
- open label
- clinical trial
- stem cells
- randomized controlled trial
- mesenchymal stem cells
- photodynamic therapy
- fluorescence imaging
- young adults
- study protocol
- cell therapy
- breast cancer risk
- early breast cancer